Exilby Authorization Highlights Non-Opioid Chronic Low

What Is Exilby for Chronic Low Back Pain?

Chronic low back pain is one of the most common causes of disability worldwide, and guidelines increasingly emphasize active, non-surgical care before invasive procedures or long-term opioid therapy. Vertanical’s announcement positions Exilby as a prescription, non-opioid option for patients whose pain persists despite standard measures such as exercise-based rehabilitation, education and selected non-opioid medicines.

The treatment has drawn attention because earlier reporting on Vertanical’s clinical program described a proprietary liquid cannabis-derived formulation tested in a randomized trial of roughly 800 adults with chronic lower back pain. The reported trial used an 11-point pain scale over 12 weeks and also assessed function, sleep and tolerability, outcomes that matter because pain intensity alone often does not capture the full burden of chronic back pain.

Why Does a Non-Opioid Back Pain Drug Matter?

The CDC’s opioid prescribing guideline stresses that opioids can be appropriate in selected circumstances but should not be the default long-term strategy for many chronic pain conditions. Risks include dependence, overdose, constipation, sedation and drug interactions, while benefits for chronic non-cancer pain can be modest and variable. That has created a strong clinical need for alternatives that can be studied under controlled dosing, quality and safety conditions.

A regulated cannabinoid-based medicine is not the same as over-the-counter or dispensary cannabis products. Prescription development requires defined composition, manufacturing controls, adverse-event monitoring and post-authorization safety surveillance. Even so, cannabinoid medicines can cause dizziness, fatigue, nausea, impaired attention and driving concerns, so a non-opioid label should not be interpreted as risk-free.

What Should Patients Know Before Exilby Reaches Wider Use?

Vertanical says a pivotal U.S. Phase 3 trial is underway, meaning the FDA will need its own assessment of efficacy, dosing, manufacturing quality and safety before the medicine could be marketed in the United States. U.S. regulators commonly ask whether trial results are clinically meaningful, whether benefits persist, and whether adverse effects are manageable in the broad population likely to use the drug.

For now, chronic low back pain care should remain multimodal: physical activity, education, sleep optimization, psychological support when needed, and careful use of medicines based on individual risk. A new drug could become useful for some patients, but it would fit into a broader pain-management plan rather than replace rehabilitation or evaluation for red-flag symptoms such as progressive weakness, fever, cancer history or bowel and bladder changes.